

Appendix 4E

Preliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited

ABN or equivalent
company reference

25 006 194 752

Financial year ended
(‘current period’)

30 June 2026

Financial year ended
(‘previous period’)

30 June 2025

2. Results for announcement to the market

ASX Listing Rules Ref		2026 A\$'000	2025 A\$'000 (*Restated)	% change
2.1	Revenue from ordinary activities	261,688	212,980	22.9%
2.2	Underlying profit before tax (minus currency gains/(losses) and fair value movement of other financial assets)	205,178	*165,247	24.2%
	Fair value movement of other financial assets	174,241	*98	N/A
	Currency gains/(losses) before tax	(1,902)	(2,033)	N/A
	Reported profit before tax	377,517	163,312	131.2%
	Income tax expense	(112,173)	(48,095)	N/A
	Profit from ordinary activities after tax attributable to members	265,344	115,217	130.3%
	*The Group's definition of Underlying Profit has been revised during the period to include interest income, which was previously excluded. This change better reflects the Group's underlying performance, and the prior corresponding period has been restated on a consistent basis. Underlying Profit for FY25 has been restated from \$157.7M to \$165.2M as a result. Underlying Profit is a non-IFRS measure and has not been audited.			
2.3	Net profit for the period attributable to members	265,344		
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	Up 130.3%		
2.4	Dividends (distributions)	Amount per security	Franked/Unfranked amount per security	
	<u>Dividend amount per security</u> Final dividend (franked)	37.0 cents	37.0 cents	
	Interim dividend (franked)	32.0 cents	32.0 cents	

2.5	Record date for Final dividends	08 September 2026	
	Payment date for Final dividends	29 September 2026	
2.6	Please refer to results commentary in the attached Financial Statements “Review and Results of Operations” section, which includes commentary on the impact of movements in foreign exchange rates and the Group’s results presented on a constant currency basis. Further detail on the constant currency information is set out in the FY26 Results Presentation released to ASX on the same date as this report.		
3.	Statement of Comprehensive Income Please refer to the Statement of Comprehensive Income in the attached Financial Statements.		
4.	Statement of Financial Position Please refer to the Statement of Financial Position in the attached Financial Statements.		
5.	Statement of cash flows Please refer to the Statement of Cash Flows in the attached Financial Statements.		
6.	Details of Dividends		
		2026 \$’000	2025 \$’000
	Final Dividend		
	A franked Final Dividend of 37.0 cents (2025: 30.0 cents) per share will be paid on 29 September 2026.	38,654	31,339
	Current Year Interim		
	A franked Interim Dividend of 32.0 cents (2025: 25.0 cents franked) per share was paid on 20 March 2026.	33,430	26,124
	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
7.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.		
8.	Statement of Retained Earnings Please refer to Statement of Changes in Equity in the attached Financial Statements.		
9.	Net Tangible Assets per security Net Tangible Assets per security	2026 \$4.10	2025 \$2.26
10.	Details of entities over which control has been gained or lost during the period There are no entities over which control has been gained or lost during the period		
11.	Associates and joint venture entities There are no associates or joint venture entities.		

12.	Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position. Please refer to section 2.6, the "Review and Results of Operations" section of the attached Financial Statements (including the constant currency information) and the FY26 Results Presentation released to ASX on the same date as this report.
13.	Foreign Entity accounting standards Australian Accounting Standards & International Financial Reporting Standards
14.	Commentary on results for the period. The earnings per security and the nature of any dilution aspects. Please refer to Note 8 of the attached Financial Statements. Returns to shareholders including distributions and buy backs. Please refer to Note 9 of the attached Financial Statements. Significant features of operating performance and discussion of trends in performance. Please refer to section 2.6. The results of segments that are significant to an understanding of the business. Please refer to Note 4 of the attached Financial Statements.
15.	Audit Statement This report is based on accounts to which one of the following applies. (Tick one) ☒ The *accounts have been audited. ☐ The *accounts have been subject to review. ☐ The *accounts are in the process of being audited. ☐ The *accounts have <i>not</i> yet been audited or reviewed.

Sign here:

Date: 18 August 2026

Print name: Sam Hupert
Chief Executive Officer